ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
News-Medical.Net on MSN22h
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIVViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ten small & medium-sized charities have been named as winners of the 2025 GSK IMPACT Awards for their work improving health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback